{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T00:14:13Z","timestamp":1794442453901,"version":"4.9.1"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"1","funder":[{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["CA234181"],"award-info":[{"award-number":["CA234181"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["CA186781"],"award-info":[{"award-number":["CA186781"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["CA190045"],"award-info":[{"award-number":["CA190045"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH NCI","doi-asserted-by":"publisher","award":["CA224018"],"award-info":[{"award-number":["CA224018"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,6,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>The most common genetic abnormality in multiple myeloma is the deletion of chromosome 13, seen in almost half of newly diagnosed patients. Unlike chronic lymphocytic leukemia, where a recurrent minimally deleted region including MIR15A\/MIR16-1 has been mapped, the deletions in multiple myeloma predominantly involve the entire chromosome and no specific driver gene has been identified. Additional candidate loci include RB1 and DIS3, but while biallelic deletion of RB1 is associated with disease progression, DIS3 is a common essential gene and complete inactivation is not observed. The Vk*MYC transgenic mouse model of multiple myeloma spontaneously acquires del(14), syntenic to human chromosome 13, and Rb1 complete inactivation, but not Dis3 mutations. Taking advantage of this model, we explored the role in multiple myeloma initiation and progression of two candidate loci on chromosome 13: RB1 and MIR15A\/MIR16-1. Monoallelic deletion of Mir15a\/Mir16-1, but not Rb1, was sufficient to accelerate the development of monoclonal gammopathy in wild-type mice and the progression of multiple myeloma in Vk*MYC mice, resulting in increased expression of Mir15a\/Mir16-1 target genes and plasma cell proliferation, which was similarly observed in patients with multiple myeloma.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance:<\/jats:title>\n                  <jats:p>In the absence of a defined, minimally deleted region the significance of del(13) in multiple myeloma has remained controversial. Here we show that haploinsufficiency of Mir15a\/Mir16-1, but not Rb1, upregulates the cell cycle\u2013regulatory network, inducing monoclonal gammopathy in mice and promoting multiple myeloma progression in both mice and men.<\/jats:p>\n                  <jats:p>See related commentary by Walker, p. 16.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 5<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/0008-5472.bcd-19-0068","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T18:48:29Z","timestamp":1583261309000},"page":"68-81","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Monosomic Loss of MIR15A\/MIR16-1 Is a Driver of Multiple Myeloma Proliferation and Disease Progression"],"prefix":"10.1158","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4024-8225","authenticated-orcid":false,"given":"Marta","family":"Chesi","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb K.","family":"Stein","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria M.","family":"Garbitt","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meaghen E.","family":"Sharik","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan W.","family":"Asmann","sequence":"additional","affiliation":[{"name":"2Division of Health Science Research, Mayo Clinic, Jacksonville, Florida."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"Matteo","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Riggs","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth J.","family":"Welsh","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin W.","family":"Meermeier","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[{"name":"3Division of Hematology and Medical Oncology, Mayo Clinic, Rochester, Minnesota."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Braggio","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,2,20]]},"reference":[{"key":"2023122218174043500_bib1","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"key":"2023122218174043500_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"key":"2023122218174043500_bib3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2011.53","article-title":"Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma","volume":"25","author":"Chng","year":"2011","journal-title":"Leukemia"},{"key":"2023122218174043500_bib4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41375-019-0543-4","article-title":"MYC dysregulation in the progression of multiple myeloma","volume":"34","author":"Misund","year":"2020","journal-title":"Leukemia"},{"key":"2023122218174043500_bib5","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"key":"2023122218174043500_bib6","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"key":"2023122218174043500_bib7","doi-asserted-by":"crossref","first-page":"e1008850","DOI":"10.1080\/2162402X.2015.1008850","article-title":"Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma","volume":"4","author":"Calcinotto","year":"2015","journal-title":"Oncoimmunology"},{"key":"2023122218174043500_bib8","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"key":"2023122218174043500_bib9","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"2023122218174043500_bib10","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2009.011064","article-title":"Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"key":"2023122218174043500_bib11","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1038\/bcj.2017.83","article-title":"Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma","volume":"7","author":"Binder","year":"2017","journal-title":"Blood Cancer J"},{"key":"2023122218174043500_bib12","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"2023122218174043500_bib13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1056\/NEJMoa075290","article-title":"Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia","volume":"359","author":"Rawstron","year":"2008","journal-title":"N Engl J Med"},{"key":"2023122218174043500_bib14","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/sj.leu.2402125","article-title":"Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy","volume":"15","author":"Fonseca","year":"2001","journal-title":"Leukemia"},{"key":"2023122218174043500_bib15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","article-title":"The DLEU2\/miR-15a\/16\u20131 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia","volume":"17","author":"Klein","year":"2010","journal-title":"Cancer Cell"},{"key":"2023122218174043500_bib16","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.15252\/embr.201643735","article-title":"The miR-15 family reinforces the transition from proliferation to differentiation in pre-B cells","volume":"18","author":"Lindner","year":"2017","journal-title":"EMBO Rep"},{"key":"2023122218174043500_bib17","doi-asserted-by":"crossref","first-page":"6669","DOI":"10.1182\/blood-2009-01-198408","article-title":"MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"2023122218174043500_bib18","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/leu.2013.139","article-title":"Degree of focal immunoglobulin heavy chain locus deletion as a measure of B-cell tumor purity","volume":"27","author":"Bergsagel","year":"2013","journal-title":"Leukemia"},{"key":"2023122218174043500_bib19","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1038\/bcj.2017.12","article-title":"Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker","volume":"7","author":"Chavan","year":"2017","journal-title":"Blood Cancer J"},{"key":"2023122218174043500_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/359295a0","article-title":"Effects of an Rb mutation in the mouse","volume":"359","author":"Jacks","year":"1992","journal-title":"Nature"},{"key":"2023122218174043500_bib21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.4049\/jimmunol.112.6.2271","article-title":"Homogeneous immunoglobulins in sera of mice during aging","volume":"112","author":"Radl","year":"1974","journal-title":"J Immunol"},{"key":"2023122218174043500_bib22","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1172\/JCI66517","article-title":"BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression","volume":"123","author":"Roccaro","year":"2013","journal-title":"J Clin Invest"},{"key":"2023122218174043500_bib23","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1111\/jcmm.12882","article-title":"MiR-16 regulates mouse peritoneal macrophage polarization and affects T-cell activation","volume":"20","author":"Jia","year":"2016","journal-title":"J Cell Mol Med"},{"key":"2023122218174043500_bib24","article-title":"MiR-16 regulates crosstalk in NF-kB tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages","volume":"4(21):e129615","author":"Khalife","year":"2019","journal-title":"JCI Insight"},{"key":"2023122218174043500_bib25","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.0800121105","article-title":"MiR-15a and miR-16\u20131 cluster functions in human leukemia","volume":"105","author":"Calin","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023122218174043500_bib26","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3892\/or.2012.1934","article-title":"MAGEA4 induces growth in normal oral keratinocytes by inhibiting growth arrest and apoptosis","volume":"28","author":"Bhan","year":"2012","journal-title":"Oncol Rep"},{"key":"2023122218174043500_bib27","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/sigtrans.2016.10","article-title":"Inhibiting cancer cell hallmark features through nuclear export inhibition","volume":"1","author":"Sun","year":"2016","journal-title":"Signal Transduct Target Ther"},{"key":"2023122218174043500_bib28","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"key":"2023122218174043500_bib29","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cell.2018.07.015","article-title":"Nuclear pores promote lethal prostate cancer by increasing POM121-driven E2F1, MYC, and AR nuclear import","volume":"174","author":"Rodriguez-Bravo","year":"2018","journal-title":"Cell"},{"key":"2023122218174043500_bib30","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1016\/j.febslet.2008.03.009","article-title":"Deciphering the assembly pathway of Sm-class U snRNPs","volume":"582","author":"Neuenkirchen","year":"2008","journal-title":"FEBS Lett"},{"key":"2023122218174043500_bib31","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature14267","article-title":"eIF3 targets cell-proliferation messenger RNAs for translational activation or repression","volume":"522","author":"Lee","year":"2015","journal-title":"Nature"},{"key":"2023122218174043500_bib32","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1073\/pnas.0506654102","article-title":"miR-15 and miR-16 induce apoptosis by targeting BCL2","volume":"102","author":"Cimmino","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023122218174043500_bib33","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/carcin\/bgs333","article-title":"miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF","volume":"34","author":"Sun","year":"2013","journal-title":"Carcinogenesis"},{"key":"2023122218174043500_bib34","first-page":"1287","article-title":"Downregulation of miRNA-15a and miRNA-16 promote tumor proliferation in multiple myeloma by increasing CABIN1 expression","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol Lett"},{"key":"2023122218174043500_bib35","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/s41375-018-0030-3","article-title":"Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance","volume":"32","author":"Lakshman","year":"2018","journal-title":"Leukemia"},{"key":"2023122218174043500_bib36","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"2023122218174043500_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","article-title":"Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma","volume":"96","author":"Hose","year":"2011","journal-title":"Haematologica"},{"key":"2023122218174043500_bib38","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1038\/s41598-018-33396-w","article-title":"The genetic landscape of 5T models for multiple myeloma","volume":"8","author":"Maes","year":"2018","journal-title":"Sci Rep"},{"key":"2023122218174043500_bib39","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1182\/blood.V94.8.2583.420a05_2583_2589","article-title":"Monosomy 13 is associated with the transition of monoclonal gammopathy of undetermined significance to multiple myeloma. Intergroupe Francophone du Myelome","volume":"94","author":"Avet-Loiseau","year":"1999","journal-title":"Blood"},{"key":"2023122218174043500_bib40","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"key":"2023122218174043500_bib41","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","article-title":"Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis","volume":"21","author":"Gutierrez","year":"2007","journal-title":"Leukemia"},{"key":"2023122218174043500_bib42","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/nar\/gkt930","article-title":"Multiple myeloma-associated hDIS3 mutations cause perturbations in cellular RNA metabolism and suggest hDIS3 PIN domain as a potential drug target","volume":"42","author":"Tomecki","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"2023122218174043500_bib43","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1182\/blood-2016-09-742296","article-title":"Prognostic role of circulating exosomal miRNAs in multiple myeloma","volume":"129","author":"Manier","year":"2017","journal-title":"Blood"},{"key":"2023122218174043500_bib44","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/leu.2014.155","article-title":"Circulating miRNA markers show promise as new prognosticators for multiple myeloma","volume":"28","author":"Rocci","year":"2014","journal-title":"Leukemia"},{"key":"2023122218174043500_bib45","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1200\/JCO.2019.37.15_suppl.8000","article-title":"Updated risk stratification model for smoldering multiple myeloma (SMM) incorporating the revised IMWG diagnostic criteria","volume":"37","author":"Miguel","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023122218174043500_bib46","doi-asserted-by":"crossref","first-page":"39165","DOI":"10.18632\/oncotarget.5381","article-title":"miRNAs in multiple myeloma\u2013a survival relevant complex regulator of gene expression","volume":"6","author":"Seckinger","year":"2015","journal-title":"Oncotarget"},{"key":"2023122218174043500_bib47","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1093\/nar\/gni179","article-title":"Evolving gene\/transcript definitions significantly alter the interpretation of GeneChip data","volume":"33","author":"Dai","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"2023122218174043500_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/1471-2105-10-161","article-title":"GAGE: generally applicable gene set enrichment for pathway analysis","volume":"10","author":"Luo","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"2023122218174043500_bib49","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","article-title":"Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma","volume":"12","author":"Keats","year":"2007","journal-title":"Cancer Cell"},{"key":"2023122218174043500_bib50","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/1\/1\/68\/3392691\/68.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/1\/1\/68\/3392691\/68.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T18:18:39Z","timestamp":1703269119000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/1\/1\/68\/35130\/Monosomic-Loss-of-MIR15A-MIR16-1-Is-a-Driver-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,20]]},"references-count":50,"aliases":["10.1158\/2643-3249.bcd-19-0068"],"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,20]]},"published-print":{"date-parts":[[2020,6,19]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.bcd-19-0068","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,20]]}}}